<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KETOROLAC TROMETHAMINE- ketorolac tromethamine solution/ drops </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>KETOROLAC TROMETHAMINE <br>ophthalmic solution 0.4%<br>sterile
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Ketorolac tromethamine ophthalmic solution 0.4% is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use.
</p>
<p>Structural and Molecular Formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="structural formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c90a3ac-ab76-405d-adc2-2f9ea3e3f250&amp;name=structuralformula.jpg">
</div>
<p><span class="Bold">Chemical Name:</span> (±)-5-Benzoyl-2,3-dihydro-1<span class="Italics">H</span>-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
</p>
<p><span class="Bold">Contains: Active:</span> ketorolac tromethamine 0.4%. 
</p>
<p><span class="Bold">Preservative:</span> benzalkonium chloride 0.006%. <span class="Bold">Inactives:</span> sodium chloride; edetate disodium 0.015%; octoxynol 40; purified water; and hydrochloric acid and/or sodium hydroxide to adjust pH.
</p>
<p>Ketorolac tromethamine ophthalmic solution is supplied as a sterile isotonic aqueous 0.4% solution, with a pH of approximately 7.4. Ketorolac tromethamine ophthalmic solution is a racemic mixture of R-(+) and S-(-)- ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. The pKa of ketorolac is 3.5. This white to off-white crystalline substance discolors on prolonged exposure to light. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of ketorolac tromethamine ophthalmic solution is approximately 290 mOsml/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Mechanism of Action</span></p>
<p>Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Pharmacokinetics</span></p>
<p>One drop (0.05 mL) of 0.5% ketorolac tromethamine ophthalmic solution was instilled into one eye and one drop of vehicle into the other eye TID in 26 normal subjects. Only 5 of 26 subjects had a detectable amount of ketorolac in their plasma (range 10.7 to 22.5 ng/mL) at day 10 during topical ocular treatment. When ketorolac tromethamine 10 mg is administered systemically every 6 hours, peak plasma levels at steady state are around 960 ng/mL. 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<p class="First"><span class="Bold Italics">Clinical Studies</span></p>
<p>In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ketorolac tromethamine 0.4% or its vehicle QID for up to 4 days. Significant differences favored ketorolac tromethamine for the reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> following photorefractive keratectomy surgery.
</p>
<p>Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure.
</p>
<p>The safety and effectiveness of ketorolac tromethamine ophthalmic solution in post-<span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery patients has not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Ketorolac tromethamine ophthalmic solution is indicated for the reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> following corneal refractive surgery.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients in the formulation.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. 
</p>
<p>With some nonsteroidal anti-inflammatory drugs there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<h2>General
</h2>
<p class="First">All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including ketorolac tromethamine ophthalmic solution, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
</p>
<p>Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> or <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
</p>
<p>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface diseases (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.
</p>
<p>Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
</p>
<p>It is recommended that ketorolac tromethamine ophthalmic solution be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications, which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s11"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s12"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Ketorolac tromethamine was neither carcinogenic in rats given up to 5 mg/kg/day orally for 24 months (156 times the maximum recommended human topical ophthalmic dose, on a mg/kg basis, assuming 100% absorption in humans and animals) nor in mice given 2 mg/kg/day orally for 18 months (62.5 times the maximum recommended human topical ophthalmic dose, on a mg/kg basis, assuming 100% absorption in humans and animals).
</p>
<p>Ketorolac tromethamine was not mutagenic <span class="Italics">in vitro</span> in the Ames assay or in forward mutation assays. Similarly, it did not result in an <span class="Italics">in vitro</span> increase in unscheduled DNA synthesis or an <span class="Italics">in vivo</span> increase in chromosome breakage in mice. However, ketorolac tromethamine did result in an increased incidence in chromosomal aberrations in Chinese hamster ovary cells.
</p>
<p>Ketorolac tromethamine did not impair fertility when administered orally to male and female rats at doses up to 280 and 499 times the maximum recommended human topical ophthalmic dose, respectively, on a mg/kg basis, assuming 100% absorption in humans and animals.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s14"></a><a name="section-6.4.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects: Pregnancy Category C</span></p>
<p>Ketorolac tromethamine, administered during organogenesis, was not teratogenic in rabbits or rats at oral doses up to 112 times and 312 times the maximum recommended human topical ophthalmic dose, respectively, on a mg/kg basis assuming 100% absorption in humans and animals. When administered to rats after Day 17 of gestation at oral doses up to 46 times the maximum recommended human topical ophthalmic dose on a mg/kg basis, assuming 100% absorption in humans and animals, ketorolac tromethamine resulted in dystocia and increased pup mortality. There are no adequate and well-controlled studies in pregnant women. Ketorolac tromethamine ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s15"></a><a name="section-6.4.2"></a><p></p>
<p class="First"><span class="Bold">Nonteratogenic Effects</span></p>
<p>Because of the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of ketorolac tromethamine ophthalmic solution during late pregnancy should be avoided.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s16"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">Caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s17"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 3 have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s18"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s19"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">The most frequently reported adverse reactions for ketorolac tromethamine ophthalmic solution occurring in approximately 1 to 5% of the overall study population were <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4232690" conceptname="Infiltrate of cornea">corneal infiltrates</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, ocular <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>.
</p>
<p>The most frequent adverse events reported with the use of ketorolac tromethamine ophthalmic solutions have been transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and burning on instillation. These events were reported by 20% - 40% of patients participating in these other clinical trials.
</p>
<p>Other adverse events occurring approximately 1% - 10% of the time during treatment with ketorolac tromethamine ophthalmic solutions included <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, ocular irritation, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, superficial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, and superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-7.1"></a><p></p>
<h2>Clinical Practice
</h2>
<p class="First">The following events have been identified during postmarketing use of ketorolac tromethamine ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solutions, or a combination of these factors, include <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span> and epithelial breakdown (see <a href="#s10">PRECAUTIONS, General</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s21"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day in the operated eye as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> for up to 4 days following corneal refractive surgery.
</p>
<p>Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s22"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Ketorolac tromethamine ophthalmic solution 0.4% is supplied sterile in an opaque white LDPE plastic bottle with a white dropper with a gray high impact polystyrene (HIPS) cap as follows:</p>
<p><span>5 mL in 10 mL bottle - NDC 54868-6416-0</span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="s23"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15°-25°C (59°-77°F).
</p>
<p><span class="Bold">Revised: 10/2013</span></p>
<p>© 2013 Allergan, Inc., Irvine, CA  92612, U.S.A.<br>® marks owned by Allergan, Inc.<br>Patented. See: www.allergan.com/products/patent_notices<br>Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Pacific Pharma Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c90a3ac-ab76-405d-adc2-2f9ea3e3f250&amp;name=pacificpharmalogo.jpg"></p>
<p>71654PY10
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="L1c494c80-57b9-469f-8182-ec24b32c9d3a"></a><a name="section-9.1.1"></a><p></p>
<p class="First"><span class="Bold">Distributed by:</span></p>
<p><span class="Bold"></span>﻿Physicians Total Care, Inc.</p>
<p>Tulsa, OK   74146</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s24"></a><a name="section-10"></a><p></p>
<p class="First">Pacific<br>Pharma<span class="Bold"><span class="Sup">®</span></span></p>
<p>NDC 60758-773-05
</p>
<p><span class="Bold">KETOROLAC<br>TROMETHAMINE<br></span>ophthalmic<br>solution, 0.4%
</p>
<p>5mL
</p>
<p>sterile
</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c90a3ac-ab76-405d-adc2-2f9ea3e3f250&amp;name=carton.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<p class="First">NDC 54868-6416-0</p>
<p>KETOROLAC TROMETHAMINE</p>
<p><img alt="package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c90a3ac-ab76-405d-adc2-2f9ea3e3f250&amp;name=6416.jpg"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETOROLAC TROMETHAMINE 		
					</strong><br><span class="contentTableReg">ketorolac tromethamine solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6416(NDC:60758-773)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ketorolac Tromethamine</strong> (Ketorolac) </td>
<td class="formItem">Ketorolac Tromethamine</td>
<td class="formItem">4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>octoxynol-40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6416-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021528</td>
<td class="formItem">03/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-6416)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5a71f9d6-9f3f-47a3-ac53-d1e0208c6f72</div>
<div>Set id: 8c90a3ac-ab76-405d-adc2-2f9ea3e3f250</div>
<div>Version: 1</div>
<div>Effective Time: 20150507</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
